Literature DB >> 9496826

Unusual dural and skull-based mesenchymal neoplasms: a report of four cases.

B K Kleinschmidt-DeMasters1, G W Mierau, C I Sze, R E Breeze, B Greffe, K O Lillehei, J K Stephens.   

Abstract

Dural and skull-base mesenchymal neoplasms other than meningiomas are rare. We report four such tumors, some of which are uncommon even in nonintracranial sites, in three adults and one child. The adult tumors consisted of a synovial sarcoma of the third ventricle region in a 19-year-old woman, a leiomyoma of the suprasellar region in a 57-year-old woman, and an Epstein-Barr virus (EBV)-associated smooth muscle tumor of the cavernous sinus in a 35-year-old woman with acquired immunodeficiency syndrome (AIDS). The pediatric tumor was an EBV-associated leiomyosarcoma of the left dural transverse sinus in a 14-year-old girl with common variable immunodeficiency syndrome. All tumors were thought to be primary in their dural or skull-base locations. The two EBV-associated smooth muscle tumors in immunocompromised patients expand the locations for EBV-associated smooth muscle tumors to dural and skull-base sites, the synovial sarcoma is unique to the intracranial space, and the sellar leiomyoma represents the third reported sellar smooth muscle tumor.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9496826     DOI: 10.1016/s0046-8177(98)90042-9

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  18 in total

1.  A clinicopathological study of diagnostically challenging meningioma mimics.

Authors:  Nandita Ghosal; Ravi Dadlani; Kanchan Gupta; Sunil V Furtado; A S Hegde
Journal:  J Neurooncol       Date:  2011-08-03       Impact factor: 4.130

2.  Primary intracranial leiomyosarcoma of the torcular Herophili associated with Fanconi anemia and allogenic stem cell transplantation.

Authors:  Michèle Aumüller; Karl-Walter Sykora; Christian Hartmann; Elvis J Hermann; Joachim K Krauss
Journal:  Childs Nerv Syst       Date:  2014-04-22       Impact factor: 1.475

3.  Primary intracranial leiomyoma: a case report and literature review.

Authors:  Abdullah E Ali; Mahmood Fazl; Juan M Bilbao
Journal:  Virchows Arch       Date:  2006-08-08       Impact factor: 4.064

4.  Oesophageal mesenchymal tumours: clinicopathological features and absence of Epstein-Barr virus.

Authors:  K Y Lam
Journal:  J Clin Pathol       Date:  1999-10       Impact factor: 3.411

5.  Primary intracranial leiomyosarcoma in an immunocompetent patient: case report.

Authors:  Yasunori Fujimoto; Junko Hirato; Akatsuki Wakayama; Toshiki Yoshimine
Journal:  J Neurooncol       Date:  2010-11-10       Impact factor: 4.130

6.  Brain involvement in multicentric Epstein-Barr virus-associated smooth muscle tumours in a child after kidney transplantation.

Authors:  Sabah Boudjemaa; Françoise Boman; Vincent Guigonis; Liliane Boccon-Gibod
Journal:  Virchows Arch       Date:  2004-04       Impact factor: 4.064

7.  Surgical management and long-term outcomes of primary intracranial leiomyosarcoma: a case series and review of literature.

Authors:  Gui-Jun Zhang; Jian-Cong Weng; Xu-Lei Huo; Jun-Peng Ma; Bo Wang; Liang Wang; Huan Li; Da Li; Jun-Ting Zhang; Zhen Wu
Journal:  Neurosurg Rev       Date:  2020-10-24       Impact factor: 3.042

Review 8.  [Primary renal synovial sarcoma. A new entity in the morphological spectrum of spindle cell renal tumors].

Authors:  H Moch; A Wodzynski; L Guillou; V Nickeleit
Journal:  Pathologe       Date:  2003-10       Impact factor: 1.011

9.  Synovial sarcoma of the sellar region.

Authors:  Bernd W Scheithauer; Ana Isabel Silva; Keith Kattner; Jason Seibly; Andre M Oliveira; Kalman Kovacs
Journal:  Neuro Oncol       Date:  2007-08-17       Impact factor: 12.300

Review 10.  Sarcomas of the sellar region: a systematic review.

Authors:  Fernando Guerrero-Pérez; Noemi Vidal; Macarena López-Vázquez; Reinaldo Sánchez-Barrera; Juan José Sánchez-Fernández; Alberto Torres-Díaz; Nuria Vilarrasa; Carles Villabona
Journal:  Pituitary       Date:  2021-02       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.